Skip to content

Application of Tegileridine in Elderly Mechanical Ventilation Patients

Application of Tegileridine in Elderly Mechanical Ventilation Patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600132166
Enrollment
Unknown
Registered
2026-09-10
Start date
2026-09-10
Completion date
Unknown
Last updated
2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain in elderly mechanical ventilation patients

Interventions

Experimental group:Tegileridine Fumarate Injection

Sponsors

Jiangsu Province Hospital (The First Affiliated Hospital with Nanjing Medical University)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age >= 65 years (gender not restricted); 2. Body Mass Index (BMI) 18.5 - 28.0 kg/m^2; 3. At the time of enrollment, mechanical ventilation had been received and the duration was less than 48 hours; 4. The expected duration of subsequent mechanical ventilation is >= 24 hours; 5. The patient voluntarily participated in this study and signed the informed consent form by themselves or their legal representative.

Exclusion criteria

Exclusion criteria: 1.Known hypersensitivity to the investigational drug or any of its excipients; 2.History of drug abuse, alcohol abuse, chronic pain, or long-term opioid use; 3.Severe psychiatric illness, or inability to undergo Richmond Agitation-Sedation Scale (RASS) or Critical-Care Pain Observation Tool (CPOT) assessment due to neuromuscular blocker use, severe central nervous system injury, or other causes; 4.Severe hepatic impairment (e.g., Child-Pugh Class C); 5.Mechanical intestinal obstruction, intestinal ischemia, gastrointestinal perforation, or severe gastrointestinal motility disorder; 6.Pregnant or lactating women; 7.Participation in another interventional clinical trial within 30 days prior to enrollment; 8.Moribund state, or an expected survival of < 48 hours as assessed by the investigator; 9.Any other condition deemed by the investigator to render the subject unsuitable for this trial;

Design outcomes

Primary

MeasureTime frame
Duration of mechanical ventilation;

Secondary

MeasureTime frame
Duration of Unconsciousness or Excessive Sedation;Rescue analgesic requirement;Sedative dosage;Rate of analgesic target attainment;Incidence of delirium;Respiratory Adverse Events (RAEs);Weaning Time;Gastrointestinal dysfunction;ICU-free days within 28 days;Ventilator-free days within 28 days;Total length of hospital stay (LOS);Rate of re-intubation;28-day all-cause mortality;

Countries

China

Contacts

Public ContactJing Zhou

Jiangsu Province Hospital (The First Affiliated Hospital with Nanjing Medical University)

jsnjzhoujing@163.com+86 25 68305051

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Sep 19, 2026